Antibody-Drug Conjugates for Cancer Therapy

被引：254

作者：

Hafeez, Umbreen ^{[1
,2
,3
]}

Parakh, Sagun ^{[1
,2
,3
]}

Gan, Hui K. ^{[1
,3
,4
]}

Scott, Andrew M. ^{[1
,3
,4
,5
]}

机构：

[1] Olivia Newton John Canc Res Inst, Tumour Targeting Lab, Melbourne, Vic 3084, Australia

[2] Olivia Newton John Canc & Wellness Ctr, Dept Med Oncol, Austin Hlth, Melbourne, Vic 3084, Australia

[3] La Trobe Univ, Sch Canc Med, Melbourne, Vic 3084, Australia

[4] Univ Melbourne, Dept Med, Melbourne, Vic 3084, Australia

[5] Austin Hlth, Dept Mol Imaging & Therapy, Melbourne, Vic 3084, Australia

来源：

MOLECULES | 2020年 / 25卷 / 20期

基金：

澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;

关键词：

antibody– drug conjugate; ADC; monoclonal antibody; cytotoxic payload; linkers; cancer; molecular imaging; ACUTE MYELOID-LEUKEMIA; PROMISING ANTITUMOR EFFICACY; TRASTUZUMAB EMTANSINE T-DM1; CELL MATURATION ANTIGEN; GEMTUZUMAB OZOGAMICIN; BRENTUXIMAB VEDOTIN; OPEN-LABEL; MULTIPLE-MYELOMA; HODGKIN LYMPHOMA; INTRACELLULAR TRAFFICKING;

D O I：

10.3390/molecules25204764

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Antibody-drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity to normal tissue, achieving wider therapeutic windows and enhanced pharmacokinetic/pharmacodynamic properties. To date, nine ADCs have been approved by the FDA and more than 80 ADCs are under clinical development worldwide. In this paper, we provide an overview of the biology and chemistry of each component of ADC design. We briefly discuss the clinical experience with approved ADCs and the various pathways involved in ADC resistance. We conclude with perspectives about the future development of the next generations of ADCs, including the role of molecular imaging in drug development.

引用

页数：33

共 185 条

[1] TAK-164, a GCC-targeted antibody-drug conjugate (ADC) for the treatment of colorectal cancers and other GI malignancies [J].

Abu-Yousif, Adnan O. ;

Bannerman, Bret M. ;

Cvet, Donna ;

Gallery, Melissa ;

Ganno, Michelle L. ;

Smith, Michael D. ;

Lai, Katharine C. ;

Keating, Thomas A. ;

Bolleddula, Jayaprakasam ;

Stringer, Bradley ;

Qian, Mark G. ;

Kamali, Afrand ;

Eng, Kurt ;

Koseoglu, Secil ;

Xia, Cindy Q. ;

Veiby, O. Petter .

MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)

[2]

ADLERSBERG J B, 1976, Ricerca in Clinica e in Laboratorio, V6, P191

[3] Efficacy of the Antibody-Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors [J].

Akla, Barbara ;

Broussas, Matthieu ;

Loukili, Noureddine ;

Robert, Alain ;

Beau-Larvor, Charlotte ;

Malissard, Martine ;

Boute, Nicolas ;

Champion, Thierry ;

Haeuw, Jean-Francois ;

Beck, Alain ;

Perez, Michel ;

Dreyfus, Cyrille ;

Pavlyuk, Mariya ;

Chetaille, Eric ;

Corvaia, Nathalie .

MOLECULAR CANCER THERAPEUTICS, 2020, 19 (01) :168-177

[4] Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding [J].

Al-Rohil, Rami N. ;

Torres-Cabala, Carlos A. ;

Patel, Anisha ;

Tetzlaff, Michael T. ;

Ivan, Doina ;

Nagarajan, Priyadharsini ;

Curry, Jonathan L. ;

Miranda, Roberto N. ;

Duvic, Madeleine ;

Prieto, Victor G. ;

Aung, Phyu P. .

JOURNAL OF CUTANEOUS PATHOLOGY, 2016, 43 (12) :1161-1166

[5] Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial [J].

Amadori, Sergio ;

Suciu, Stefan ;

Selleslag, Dominik ;

Aversa, Franco ;

Gaidano, Gianluca ;

Musso, Maurizio ;

Annino, Luciana ;

Venditti, Adriano ;

Voso, Maria Teresa ;

Mazzone, Carla ;

Magro, Domenico ;

De Fabritiis, Paolo ;

Muus, Petra ;

Alimena, Giuliana ;

Mancini, Marco ;

Hagemeijer, Anne ;

Paoloni, Francesca ;

Vignetti, Marco ;

Fazi, Paola ;

Meert, Liv ;

Ramadan, Safaa Mahmoud ;

Willemze, Roel ;

de Witte, Theo ;

Baron, Frederic .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (09) :972-+

[6] FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer [J].

Amiri-Kordestani, Laleh ;

Blumenthal, Gideon M. ;

Xu, Qiang Casey ;

Zhang, Lijun ;

Tang, Shenghui W. ;

Ha, Linan ;

Weinberg, Wendy C. ;

Chi, Bo ;

Candau-Chacon, Reyes ;

Hughes, Patricia ;

Russell, Anne M. ;

Miksinski, Sarah Pope ;

Chen, Xiao Hong ;

McGuinn, W. David ;

Palmby, Todd ;

Schrieber, Sarah J. ;

Liu, Qi ;

Wang, Jian ;

Song, Pengfei ;

Mehrotra, Nitin ;

Skarupa, Lisa ;

Clouse, Kathleen ;

Al-Hakim, Ali ;

Sridhara, Rajeshwari ;

Ibrahim, Amna ;

Justice, Robert ;

Pazdur, Richard ;

Cortazar, Patricia .

CLINICAL CANCER RESEARCH, 2014, 20 (17) :4436-4441

[7] Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate [J].

Anderson, Mark G. ;

Falls, Hugh D. ;

Mitten, Michael J. ;

Oleksijew, Anatol ;

Vaidya, Kedar S. ;

Boghaert, Erwin R. ;

Gao, Wenqing ;

Palma, Joann P. ;

Cao, Diana ;

Chia, Puey-Ling ;

John, Thomas ;

Gan, Hui K. ;

Scott, Andrew M. ;

Reilly, Edward B. .

MOLECULAR CANCER THERAPEUTICS, 2020, 19 (10) :2117-2125

[8]

[Anonymous], 2011, ASCO M ABSTR S, DOI DOI 10.1200/JCO.2011.29.15_SUPPL.8013

[9]

[Anonymous], GEN DRUG SENS CANC

[10]

[Anonymous], 2018, J CLIN ONCOL S

← 1 2 3 4 5 6 7 8 9 10 →